Abstract
BackgroundControversy persists regarding the use of febuxostat (FBX) in patients with gout and the development of cardiovascular (CV) events. In both APEX1 and FACT2 trials a higher risk was identified...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
